Zucaglim M2 Forte Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 1000mg, formulated for sustained release. It is primarily indicated for the management of type 2 diabetes mellitus in patients whose blood glucose levels are inadequately controlled by diet, exercise, and monotherapy. Glimepiride, a sulfonylurea class agent, acts by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. The sustained-release formulation ensures a gradual release of active ingredients, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. Zucaglim M2 Forte Tablet SR should be administered once daily with meals to optimize absorption and minimize adverse effects. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerance. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or those at risk of lactic acidosis. This combination therapy offers a synergistic approach to glycemic management, improving patient compliance and reducing the risk of diabetes-related complications.